57. **Amishima M**, Munakata M, Nasuhara Y, *et al*. Expression of epidermal growth factor and epidermal growth factor receptor immunoreactivity in the asthmatic human airway. *Am J Respir Crit Care Med* 1998;**157**:1907–12.
58. **Puddicombe SM**, Polosa R, Richter A, *et al*. Involvement of the epidermal growth factor receptor in epithelial repair in asthma. *Faseb J* 2000;**14**:1362–74.
59. **Mullings RE**, Wilson SJ, Puddicombe SM, *et al*. Signal transducer and activator of transcription 6 (STAT-6) expression and function in asthmatic bronchial epithelium. *J Allergy Clin Immunol* 2001;**108**:832–8.
60. **Sampath D**, Castro M, Look DC, *et al*. Constitutive activation of an epithelial signal transducer and activator of transcription (STAT) pathway in asthma. *J Clin Invest* 1999;**103**:1353–61.
61. **Holgate ST**, Lackie P, Wilson S, *et al*. Bronchial epithelium as a key regulator of airway allergen sensitization and remodeling in asthma. *Am J Respir Crit Care Med* 2000;**162**:S113–7.
62. **Foresi A**, Leone C, Pelucchi A, *et al*. Eosinophils, mast cells, and basophils in induced sputum from patients with seasonal allergic rhinitis and perennial asthma: relationship to methacholine responsiveness. *J Allergy Clin Immunol* 1997;**100**:58–64.
63. **Serhan CN**. Lipoxins and aspirin-triggered 15-*epi*-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. *Prostaglandins Leukot Essent Fatty Acids* 2005;**73**:141–62.
64. **Bonnans C**, Fukunaga K, Levy MA, *et al*. Lipoxin A(4) regulates bronchial epithelial cell responses to acid injury. *Am J Pathol* 2006;**168**:1064–72.
65. **Chiang N**, Arita M, Serhan CN. Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. *Prostaglandins Leukot Essent Fatty Acids* 2005;**73**:163–77.
66. **Bonnans C**, Gras D, Chavis C, *et al*. Synthesis and anti-inflammatory effect of lipoxins in human airway epithelial cells. *Biomed Pharmacother* 2007;**61**:261–7.

Lung alert

Diarylquinoline TMC207 as potential new therapy for multidrug-resistant tuberculosis

TMC207 is an investigational diarylquinoline which inhibits mycobacterial ATP synthase in drug-sensitive and drug-resistant *Mycobacterium tuberculosis* in vitro. It is bactericidal to dormant tubercle bacilli, therefore offering a new mechanism for the treatment of multidrug-resistant tuberculosis.

This study is the first stage of a phase 2 randomised controlled trial. Conducted in South Africa, newly diagnosed patients with pulmonary tuberculosis resistant to both isoniazid and rifampin were randomly assigned to TMC207 or placebo in a double-blind manner in combination with a standard five-drug second-line antituberculosis regime and given over an 8-week period. The primary end point was the conversion of sputum cultures from positive to negative; the study also collected further pharmacokinetic, safety and adverse event data.

Of the initial 47 patients (predominantly HIV-negative black men with a median age of 33 years), 41 completed the 8-week course. The addition of TMC207 to the standard drug regime resulted in a quicker conversion to negative sputum culture, with 48% of the patients receiving TMC207 having a negative culture at 8 weeks compared with 9% of those given placebo (hazard ratio 11.8, 95% confidence interval 2.3 to 61.3; $p = 0.003$). Similar proportions of patients completed both courses with a similar side effects profile consistent with antituberculosis therapy; only nausea occurred significantly more frequently in the TMC207 group.

This study shows quicker conversion of sputum cultures in patients on the TMC207 regimen, highlighting its potential as antituberculous treatment in multidrug-resistant tuberculosis.

- Diacon AH, Pym A, Grobusch M, *et al*. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. *N Engl J Med* 2009;**360**:2397–405.

E Tevendale

Correspondence to: Dr E Tevendale, CMT1, St James University Hospital, Leeds, UK; ewantevendale@nhs.net

Provenance and peer review: Commissioned; not externally peer reviewed.

Thorax 2009;**64**:1004. doi:10.1136/thx.2009.122887